Introduction
Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous cancer in males of Western countries and the second leading cause of cancer-related deaths in this population (Jemal et al., 2008) . The androgen receptor (AR) plays a critical role in the growth, differentiation and function of the prostate, and is also involved in the initiation and progression of PCa. Animal models clearly indicate that AR overexpression in prostatic epithelial cells triggers proliferation and oncogenic transformation (Stanbrough et al., 2001; Berger et al., 2004) . In PCa patients, high AR levels are associated with aggressive clinicopathological features and a decreased biochemical recurrence-free survival . Moreover, increased or abnormal AR activity has been proposed as a key factor in the progression of PCa to androgen ablation therapy resistance (Linja et al., 2001; Edwards et al., 2003) . Using cDNA micro arrays as tools for the determination of markers responsible for resistance to anti-androgen therapy, an increased AR expression was identified as a unique factor consistently associated with the development of a hormone-refractory disease (Chen et al., 2004) . The introduction of a wild-type (wt) AR in the PCa cell line, LNCaP, promoted cell growth in the presence of low androgen concentrations, and shortened the latency of tumor formation upon xenografting in castrated mice (Chen et al., 2004) .
According to the central function of AR in PCa, much attention has been paid to the identification of molecules and mechanisms that determine its expression and activity, which might provide new target structures for the treatment of PCa. AR activity is modulated by different signal-transduction pathways (Reddy et al., 2006) , by cyclins (Olshavsky et al., 2008) , by interaction with numerous co-activators and repressors (Heemers and Tindall, 2007) and by diverse posttranslational modifications, including the covalent conjugation of the small ubiquitin-like protein, SUMO-1 (Callewaert et al., 2004) . In addition, mutations preferentially occurring in the ligand-binding domain of AR in advanced PCa modify ligand specificity, thereby decreasing the dependence on androgens for the stimulation of proliferation (Taplin and Balk, 2004) . There exist distinct mechanisms influencing the AR mRNA and protein expression patterns, such as autoregulation after ligand binding (Yeap et al., 1999) , transcriptional and posttrancriptional regulation as well as modification of protein stability triggered through other signaling pathways.
In this context, cytokines can act as transcriptional modulators of the AR gene expression. Tumor necrosis factor-a and interleukin-1b downregulate the AR mRNA expression by nuclear factor-k B activation (Culig et al., 1998; Ko et al., 2008) , whereas interleukin-6 and type I interferons (IFNs) mediate an AR upregulation (Lin et al., 2001; Basrawala et al., 2006) .
Interferon-stimulated gene 15 (ISG15), originally identified as a protein induced by type I IFNs (Korant et al., 1984) , is a member of the ubiquitin-like protein superfamily. Similar to ubiquitin, ISG15 is covalently conjugated to cytoplasmic and nuclear proteins, which function in diverse cellular pathways (Zhao et al., 2005) . The coupling of ISG15 to its targets is a mechanism similar to the attachment of ubiquitin, and involves the ISG15-specific E1-like activating enzyme, Ube1L (Yuan and Krug, 2001) , and the E2 enzyme, UbcH8, which also functions in ubiquitin conjugation (Kim et al., 2004; Zhao et al., 2004) . Recently, two ubiquitin ligases, the estrogen-responsive finger protein (EFP) (Zou and Zhang, 2006) and Herc5 (Dastur et al., 2006) , have been described to participate in ISG15 ligation. A major feature of the ISGylation system is the upregulation of all constituents by type I IFNs. So far, the biological function of ISGylation has only been elucidated for some cellular target proteins. These include the functional inhibition of enzymes Takeuchi et al., 2006; Zou et al., 2007; Malakhova and Zhang, 2008) and the enhancement of the cap structure-binding activity of the translational suppressor, 4EHP (Okumura et al., 2007) . Recent studies have shown that ISGylation negatively regulates the ubiquitin-proteasome pathway by direct interference with polyubiquitination (Desai et al., 2006) . Furthermore, a potential involvement of the ISGylation system in oncogenesis and tumor progression has been documented by the dysregulated expression of ISGylation components in tumors of different histological origin Feng et al., 2008) , which could be associated with a poor prognosis of patients (Bektas et al., 2008) . In addition, an altered ISG15 regulation is correlated with susceptibility/ resistance to chemotherapeutics and radiation, suggesting that ISG15 can serve as a novel biomarker for drug sensitivity (Desai et al., 2008; Weichselbaum et al., 2008) .
Here, we show for the first time (i) that all components of the ISGylation system are regulated by androgens through AR signaling in PCa cells and (ii) that an androgen ablation treatment of PCa patients modulates the expression level of the ISGylation system. Moreover, most ISGylation components were upregulated in PCa lesions when compared with that in the corresponding non-malignant tissues. Importantly, our data suggest a novel function of the ISGylation system in the regulation of AR mRNA and protein levels in PCa cells, directly affecting their proliferative capacity in the presence of androgens and under reduced androgen exposure.
Results
Overexpression of components of the ISGylation system in PCa and their regulation during androgen ablation To evaluate the potential relevance of the ISGylation system in PCa, the mRNA expression of the ISGylation components normalized to b-actin was analysed in paired tumor-derived and normal prostate tissue samples from 14 PCa patients who underwent radical prostatectomy as primary therapy and from three PCa cell lines (Table 1) . There exists a heterogeneous expression pattern of the five ISGylation components in both PCa lesions and normal prostate tissues, with the lowest mean transcription level for Ube1L, followed by ISG15. When compared with the corresponding nonmalignant prostate tissues, the PCa tumor biopsies exhibit 1.5-to 2.9-fold higher mean and median expression levels of all components, with the exception of Ube1L (Table 1 ). The upregulation in PCa was statistically significant for ISG15 and UbcH8 (paired Student's t-test). The comparative analyses indicated at least a 1.5-fold increase of ISG15 and UbcH8 transcripts in 71 and 64% of PCa lesions, respectively. It is noteworthy that the PCa cell lines showed significantly lower transcription levels than did the tumor lesions for most components (Table 1) .
To determine whether the transcription levels of the ISGylation system are modulated by androgens in situ, tumor biopsies from five PCa patients who received androgen deprivation therapy by anti-androgens or luteinizing hormone-releasing hormone (LHRH), analoga, were further analysed. Comparative studies of tumor lesions from PCa patients with or without androgen ablation treatment showed a significant increase in ISG15, Ube1L and UbcH8 transcripts by androgen ablation in all five, and for EFP, in four out of five tumor biopsies of treated patients, when compared with the mean and median expressions in the untreated tumors (Table 1) . In contrast, the Herc5 transcripts were significantly decreased in all five tumors (Table 1) .
The dysregulation of the ISGylation system in tumor versus normal prostate samples was further confirmed by the normalization of the transcript levels to the alternative housekeeping gene, hypoxanthine guanine phosphoribosyltransferase, instead of b-actin (Supplementary information 1).
Regulation of the ISGylation system by androgens in AR
þ PCa cells The regulation of the ISGylation components by androgen deprivation in situ suggested a modulation of the ISGylation system by androgens. To confirm and define the molecular mechanisms of androgen dependency, the androgen-sensitive, AR þ PCa tumor cell line, LNCaP, was cultured in the presence or absence of the synthetic AR agonist, R1881, with dihydrotestosterone (DHT) or with the solvent dimethyl sulfoxide for 24 h. The efficacy of the androgen treatment was proven by prostate-specific antigen (PSA) upregulation and AR mRNA downregulation by androgens (Figures 1a and b) .
The role of the ISGylation system in prostate cancer A Kiessling et al A significant androgen-mediated downregulation of ISG15, Ube1L, UbcH8 and EFP, with prominent changes in the mRNA expression levels of Ube1L and UbcH8 (Figures 1c-f ), was detected, whereas Herc5 transcripts were markedly upregulated under these conditions (Figure 1g ). To exclude the effects of the AR mutation in the ligand-binding domain in LNCaP cells on the regulation of the ISGylation system, the AR wt PCa cell line, VcaP, was included in these analyses. For this cell line, all regulatory effects mediated by androgens were similar to those found in LNCaP cells (Supplementary information 2) . Dose-response analyses showed that already 0.1 nM DHT caused a significant change in the mRNA levels of all ISGylation components (data not shown). Although the time kinetics of androgen effects revealed a maximal drop in ISG15, Ube1L, UbcH8 and EFP mRNA expressions after 24 h of treatment, a downregulation of UbcH8 and EFP transcripts was already detected 6 h after androgen supplementation, as exemplarily shown in Figures 2b and c for ISG15 and UbcH8. Interestingly, the duration of the effect was dependent on the ISGylation component and the respective androgen analysed. Although the DHT-mediated downregulation of ISG15 completely disappeared after 4 days, the decline was still obvious after 4 days of R1881 treatment. Significantly reduced transcription levels were detected for Ube1L, UbcH8, EFP and AR between 24 h and 4 days of androgen treatment (Figure 2c , exemplary for UbcH8). In contrast, increased mRNA levels were detected for PSA and Herc5 between 6 h and 4 days after androgen stimulation (Figures 2a and d) .
The androgen ablation of androgen-stimulated LNCaP cells completely reversed the androgenmediated downregulation of ISG15, Ube1L and AR mRNA within 24 h, whereas mRNA levels of UbcH8 and EFP were still significantly decreased 24 h after androgen ablation (Supplementary information 3) . In contrast, the androgen-mediated effects on Herc5 and PSA expressions were stable for at least 6 days of androgen ablation (data not shown).
The AR dependence of the androgen-mediated regulation of the ISGylation system was assumed by the absence of an altered expression pattern of all AR signaling is essential for the androgen-mediated regulation of the ISGylation system One might speculate that the estrogen receptor-b (ER-b), expressed in LNCaP cells (Takahashi et al., 2007) , is involved in the androgen-mediated regulation, as ERb can be cross-activated by androgens in LNCaP cells (Maggiolini et al., 2004) . On the basis of this knowledge, LNCaP cells were stimulated with androgens for 24 h in the absence or presence of the anti-estrogen, fulvestrant, and the anti-androgen, bicalutamide. The efficacy of the fulvestrant-and bicalutamide-mediated blockade of estrogen and androgen signaling was proven by the inhibition of the 17b-estradiol (E2)-and R1881-mediated upregulation of PSA mRNA, respectively (Takahashi et al., 2007) (Figure 3a ). Treatment with fulvestrant changed neither the constitutive expression in the absence of androgens nor the androgen-mediated effects on the Ube1L, UbcH8, EFP and Herc5 transcript levels when compared with those in the negative control. In contrast, bicalutamide significantly blocked the androgen-mediated effects, suggesting a role of AR in the regulation of these genes as representatively shown for UbcH8 and Herc5 (Figures 3c and d) . It is noteworthy that ISG15 was already downregulated by fulvestrant alone and, therefore, fulvestrant was not suited to evaluate the involvement of ER in the androgen-mediated effects on ISG15 (Figure 3b ). However, a complete inhibition of the androgen-mediated effects on the ISG15 expression in the presence of bicalutamide was also found (Figure 3b ). In VCaP cells, all effects could be efficiently blocked by bicalutamide as well as by hydroxyflutamide, which does not function as an antagonist for the mutated AR in LNCaP cells (Supplementary information 2).
In addition, small interfering RNA (siRNA) specific for AR was used to inhibit AR mRNA and protein expressions in LNCaP cells ( Figure 4a , Supplementary information 5). This approach allows to determine whether the androgen-mediated alterations of the expression of the ISGylation components were affected by AR downregulation. The siRNA-mediated downregulation of the AR transcript levels was accompanied by an abrogation of the androgen-mediated upregulation of PSA mRNA ( Figure 4b ). As AR siRNA also significantly inhibited the effects of androgen supplementation on all ISGylation components, a crucial role of AR in the androgen-mediated regulation of the ISGylation system can be concluded, as exemplarily shown for ISG15, UbcH8 and Herc5 (Figures 4c-e) .
The tumor suppressor, p53, was postulated as a potential mediator for the regulation of the ISGylation system by androgens (Mitsui et al., 1999; Liu et al., 2004) , as (i) AR activation inhibits p53 accumulation in the nucleus (Nantermet et al., 2004) and (ii) p53 was transcriptionally downregulated in LNCaP cells by androgens (Supplementary information 6) . By the 
The role of the ISGylation system in prostate cancer
A Kiessling et al siRNA-mediated knockdown of p53 in wt p53-expressing LNCaP cells (Van Bokhoven et al., 2003) followed by starvation in the absence of androgens, an androgenlike effect on Ube1L was mimicked by significantly reduced Ube1L transcript levels, indicating the role of p53 in the expression of Ube1L (Supplementary information 6). In contrast, none of the other ISGylation components was regulated by p53 knockdown under starving conditions. When stimulated with the androgen, the p53 level significantly decreased, and this effect could be potentiated by treatment with p53 siRNA (Supplementary information 6). The Ube1L transcript level, which reduced as a consequence of androgen treatment, was further decreased by p53 siRNA. Furthermore, the androgen-mediated Herc5 upregulation was enhanced in p53 knockdown cells, indicating p53 as a negative regulator of Herc5. However, as no significant increase in the Herc5 expression was detected after the siRNA-mediated p53 blockade in androgen-starved cells, p53 cannot be the exclusive mediator of the androgen-induced upregulation of Herc5.
Involvement of the ISGylation system in the regulation of AR mRNA expression in PCa cells
Owing to the increased expression of different ISGylation components in PCa tissues when compared with those in non-malignant prostate samples, and their regulation after androgen ablation, the ISGylation system might be involved in the modulation of tumor growth and/or in the development of androgen-refractory tumors. As a co-regulation of AR mRNA with the ISG15, Ube1L, UbcH8 and EFP transcripts was found during the androgen treatment of LNCaP cells, a regulatory link between the ISGylation components and AR expression was postulated. To strengthen this hypothesis, LNCaP cells were treated with IFN-b, which is known to induce ISGylation components . Not only the transcription of the ISGylation components but also that of AR and PSA was enhanced by IFN-b, supporting a possible regulatory association of AR to the ISGylation system ( Figure 5 ). The direct effect of the ISGylation system on the AR expression was determined using a transient overexpres- The role of the ISGylation system in prostate cancer A Kiessling et al sion of His-tagged ISG15 and myc-tagged Ube1L in LNCaP cells. As shown in Figure 6 , the Ube1L overexpression alone and a combination of the ISG15 and Ube1L overexpression resulted in approximately 4.5-fold and 5.7-fold increased AR transcript levels and a corresponding upregulation of the AR protein expression, respectively, whereas the ISG15 overexpression alone did not affect the AR expression. The AR transcript levels were not influenced by the transient overexpression of myc-tagged UbcH8 (data not shown). These results were further verified by the transient knockdown of ISG15 and Ube1L in LNCaP cells using respective siRNA (Figure 7a , see Supplementary information 7). The Ube1L transcription was partially reduced by ISG15 siRNA, indicating an association between both ISGylation components (Figure 7a ). The knockdown of the Ube1L expression alone or in combination with ISG15 siRNA, but not the ISG15 silencing alone, resulted in a significant downregulation of AR mRNA and protein expressions in LNCaP cells (Figures 7a and b) . Thus, Ube1L represents the key factor for the modulation of the AR expression, indicating either a regulatory function of Ube1L independent from its function as an ISG15-activating enzyme or, alternatively, Ube1L as a limiting factor of the ISGylation system in LNCaP cells.
To elucidate the role of ISG15 in AR regulation in this context, ISG15 was silenced in LNCaP cells stably overexpressing myc-Ube1L. The knockdown of Ube1L in His-ISG15-transfected LNCaP cells served as control. Although the proportional downregulation of AR transcripts by Ube1L siRNA did not significantly differ between mock and His-ISG15 cultures (data not (Figure 8a ). In addition, the myc-Ube1L-transfected cells are larger in size when compared with wt and mock-transfected cells (Supplementary information 9). However, studies of AR localization in LNCaP cells, cultured in the presence or absence of androgens, revealed no effect of mycUbe1L on the subcellular distribution of AR (Supplementary information 9). The proliferation of mycUbe1L transfectants in the presence of 10% fetal bovine serum (FBS) when compared with that in the respective mock culture was significantly increased, resulting in a 2.2-fold decreased doubling time, thereby suggesting an AR-dependent pro-proliferative effect of Ube1L (Figure 8b ). Transfection of the empty vector markedly decreased cell proliferation in comparison with that in wt LNCaP cells (Figure 8b ). However, the proliferation of myc-Ube1L-overexpressing cells was also significantly higher than that of wt LNCaP cells. Accordingly, AR À PC-3 cells lack an increased proliferation after myc-Ube1L overexpression (Supplementary information 10).
Furthermore, LNCaP cells were either kept under starvation conditions or stimulated with androgens for 4 days. The AR mRNA was downregulated after androgen stimulation in both wt and stably mycUbe1L-transfected LNCaP cells (Figure 8c ), whereas AR mRNA and protein levels were elevated by a maximal factor 2 on androgen starvation in mycUbe1L-transfected cells when compared with that in The role of the ISGylation system in prostate cancer A Kiessling et al mock control (Figure 8c ). Accordingly, a significantly higher proliferation of myc-Ube1L-transfected LNCaP cells was found in the presence and, remarkably, also in the absence of exogenously added androgen related to wt and mock-transfected cells (Figure 8d ). In contrast, the proliferation of AR À , androgen-independent PC-3 cells was not altered in the presence of androgens, and the myc-Ube1L overexpression did not result in increased proliferation (Supplementary information  10) . The results of the XTT assays were further verified by the determination of cell numbers on androgen starvation and supplementation (data not shown).
Discussion
Using gene expression profiling, androgens have been shown to regulate immune inflammatory response genes, including members of the IFN pathway (Desai et al., 2004; Asirvatham et al., 2006) . Our study extends these data to the different components of the ISGylation system. So far, only EFP has been described in the context of steroid regulation. The estrogen-mediated upregulation of EFP detected in breast cancer cells depends on an estrogen-responsive element in the 3 Cells were cultured in 96-well plates for 2, 4 or 6 days in a culture medium supplemented with 10% fetal bovine serum and analysed for proliferation by XTT assays. The spectrometrical absorbance was normalized by that measured for wt cells after 2 days of growth, and is depicted as relative proliferation. Shown are the mean values of six independent determinations. Significantly increased relative proliferation compared with that in the corresponding mock-transfected control is indicated by *Po0.05 and **Po0.01, as determined by Student's t-test. (c) LNCaP cells (wt, mock, mycUbe1L-transfected) starved for 2 days were stimulated with androgens at the indicated concentrations, treated with the solvent dimethyl sulfoxide (DMSO) or medium without androgens for 4 days and then used for RNA preparation and quantitative detection of AR mRNA normalized by b-actin. For cells kept in medium without androgens, AR was also analysed on the protein level by western blot analysis. A significantly increased AR expression compared with that in the corresponding mock-transfected control is indicated by *Po0.05. (d) LNCaP cells (wt, mock, myc-Ube1L-transfected) were starved and stimulated as indicated under (c) in 96-well plates. Thereafter, proliferation was determined by XTT assays. Spectrometrical absorbance was normalized by that measured for wt cells treated with DMSO alone. Shown are the mean values of six independent determinations. Significantly increased relative proliferation compared with the corresponding mock-transfected control is indicated by **Po0.01, as determined by Student's t-test. All bars indicate the s.e. of the mean.
The role of the ISGylation system in prostate cancer A Kiessling et al concern the role of EFP in the ISGylation than in the ubiquitination of target proteins. Although the mechanisms for the coordinated downregulation of ISG15, Ube1L, UbcH8 and EFP in LNCaP cells have not yet been defined, p53 represented a transcription factor potentially linking androgen signaling with the ISGylation system, and was therefore analysed in this study. Using promoter prediction software, multiple p53-binding sites were detected in the promoters of these genes. Moreover, ISG15 was identified as a p53 target gene (Polyak et al., 1997) . This is in line with a recent report coupling the sensitivity to IFN to DNA damage (Khodarev et al., 2007; Desai et al., 2008) . In addition, the chemotherapy-mediated ISG15 induction required a functional p53 protein (Liu et al., 2004) , which is also expressed by LNCaP cells. Interestingly, AR activation inhibited p53 accumulation in the nucleus as an early event in androgen-stimulated proliferation (Nantermet et al., 2004) , and the androgen stimulation of LNCaP cells mediated a significant downregulation of p53 mRNA and protein through androgen-responsive elements in the p53 gene (Supplementary information 6; Rokhlin et al., 2005) , thereby probably promoting the downregulation of the ISGylation components. The Herc5-mediated upregulation by androgens seems to be because of an indirect mechanism of androgen action as no androgen-responsive elements were predicted in a 2000 bp region upstream from the transcription start and within the gene. Interestingly, functional p53 caused a decreased Herc5 expression (Mitsui et al., 1999) , which suggested that p53 represents a potential factor for Herc5 upregulation by the nuclear exclusion of p53 in the presence of androgens.
In our studies on LNCaP cells, a siRNA-mediated knockdown of p53 mimicked the effects of androgen supplementation solely on the Ube1L expression, but not on any other ISGylation component. Thus, Ube1L was the only factor regulated by p53 in this cell line.
The role of ISGs in the initiation and progression of tumors is controversially discussed. As type I IFNs exert potent antitumor activity in mouse models and in clinical trials in different malignancies (Borden et al., 2000) , IFN-stimulated genes as key mediators of IFN activity were rather interpreted to act as tumor suppressors. This is supported by the fact that ISG genes are often mutated or dysregulated in malignant diseases (Kalvakolanu, 2000) . Indeed, many ISGs could inhibit cell proliferation, induce differentiation or stimulate antitumoral immune and anti-angiogenic responses. On the basis of the pleiotropic activities of IFNs, some downstream mediators, however, may also trigger tumorigenesis, especially when the upregulation is uncoupled from complex IFN-induced responses. In PCa, IFNs not only inhibit the proliferation of PCa cells (Sica et al., 1994) but also upregulate the AR expression (Sica et al., 1994; Basrawala et al., 2006) known to exhibit growth-promoting effects (Stanbrough et al., 2001; Berger et al., 2004) .
The ISGylation system is dysregulated in different tumor types. When compared with non-malignant tissues, ISG15 is upregulated in endometrial tumors (Desai et al., 2006) , pancreatic adenocarcinomas (Iacobuzio-Donahue et al., 2003) , breast cancer (Bektas et al., 2008) and in bladder cancer independent from inflammation . In some cases, this upregulation was associated with enhanced metastatic capacity as well as with poor patient prognosis (Bektas et al., 2008) In contrast, Ube1L is often lost or downregulated in lung cancer, indicating a tumorsuppressor function of Ube1L in this tissue (Pitterle et al., 1998) . The EFP expression is increased in advanced breast tumors and positively correlates with a poor prognosis (Sakuma et al., 2005; Suzuki et al., 2005) , which seems to be tightly connected to the specific function of EFP in the regulation of ER activity. As these distinct dysregulated expression patterns of the ISGylation system may reflect the tissue-specific functions of the components, an upregulation of ISG15, UbcH8, EFP and Herc5 in PCa is probably associated with a tissue-specific function of the ISGylation system in AR regulation.
Different results of our study clearly indicate the role of the ISGylation system in the regulation of AR mRNA and protein expressions. First, ISG15, Ube1L, UbcH8 and EFP were co-regulated with AR mRNA after androgen stimulation and in the presence of IFN-b. Second, the overexpression of Ube1L, which represents the limiting factor of the system in LNCaP cells, led to an increase in AR expression, whereas the knockdown of Ube1L decreased its expression. Third, when Ube1L was overexpressed in LNCaP cells, ISG15 siRNA resulted in a drop in AR expression, indicating the involvement of the ISGylation system rather than an independent regulatory function of Ube1L. However, the function of both the ligases in this context has to be elucidated in future studies. As EFP is co-regulated with ISG15, Ube1L and UbcH8 by androgens and antiandrogens, we postulate that this ligase exerts a function in AR regulation. The molecular mechanism connecting ISGylation with AR expression is so far unidentified. AR gene transcription and AR mRNA stability are determined by multiple signal-transduction events (Gong et al., 1995; Ko et al., 2008) . The ISGylation of key regulators of signal transduction and transcription factors has been documented in different studies (Malakhov et al., 2003; Giannakopoulos et al., 2005) . In addition, ISG15 seems to exert tumor-specific nuclear functions . Consequently, the ISG15 modification of signal-transduction molecules or transcription factors that modulate AR expression is the presumed mechanism for the regulation of AR levels in LNCaP cells.
In this study, we further show that Ube1L overexpression is accompanied by an increased proliferation of LNCaP cells in the presence of androgens and, more importantly, under conditions of reduced androgen exposure by short-time androgen starvation. Together with the increased expression of ISG15, Ube1L, UbcH8 and EFP after androgen deprivation in PCa patients, this observation indicates the involvement of the system in the progression to androgen ablation therapyresistant tumors. Although the role of AR in androgen-refractory PCa is not completely understood, AR upregulation was recognized as an early event in the transformation process of PCa from a hormonesensitive to a hormone-resistent stage that promotes tumor growth in the presence of low androgen concentrations (Gregory et al., 2001a; Chen et al., 2004) . In addition, AR downstream signaling is maintained in androgen-refractory tumors independent from androgens. The relevant mechanisms concern other signaling pathways inducing AR phosphorylation (Craft et al., 1999; Gioeli et al., 2002) and the dysregulated expression of the co-regulators of AR promoting the ligand-independent activation of AR (Gregory et al., 2001b) . Following these observations, the ISGylation system can be considered to participate in the maintenance or upregulation of the AR expression during the onset of hormone-refractory Pca, thereby promoting tumor growth at low levels of the remaining androgen. Therefore, intervening with the expression of the ISGylation system may provide new treatment options for advanced PCa.
Materials and methods
Cell culture, reagents and treatments LNCaP and PC-3 cells (both from American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in phenol-red-free RPMI1640 (PAA Laboratories, Pasching, Austria), supplemented with 2 nM L-glutamine (Cambrex Bio Science, Verviers, Belgium), 7.5 mM HEPES (CC pro, Oberdorla, Germany), 100 mg/ml penicillin and streptomycin (both from PAA Laboratories) and 10% FBS (Invitrogen, Carlsbad, CA, USA). VCaP cells (ATCC) were maintained in phenol-red-free Dulbecco's modified Eagle's medium high glucose with L-glutamine and HEPES (Invitrogen), supplemented with 1 mM sodium pyruvate and 20% FBS.
For the determination of the androgen-mediated effects, 5 Â 10 5 LNCaP cells, 2 Â 10 5 PC-3 cells or 3 Â 10 6 VCaP cells were cultured in 25 cm 2 culture flasks in a complete culture medium for 24 h, before the medium was replaced by a medium without FBS. Androgen stimulation was started 24 h later in a medium supplemented with 10 or 20% of charcoaldextran-treated FBS (CTF; HyClone, Logan, UT, USA) for LNCaP and PC-3 cells or VCaP cells, respectively, and with variable concentrations of R1881 (methyltrienolone; PerkinElmer Life Sciences, Rodgau, Germany), DHT (Sigma-Aldrich, St Louis, MO, USA) or the solvent dimethyl sulfoxide, respectively, for the indicated time periods. For determination of the stability of the androgen-mediated effects, starved LNCaP cells were stimulated with androgens for 24 h. Subsequently, the medium was replaced by a medium with 10% CTF and cultivation was continued for 24 h. For steroid receptor blocking, androgen stimulation for 24 h was carried out in the presence of 10 mM bicalutamide (Casodex; Astra Zeneca, Wilmington, DE, USA), 1 mM hydroxyflutamide (Chemos, Regenstauf, Germany) or 1 mM fulvestrant (ICI 182,780; Sigma-Aldrich). The efficacy of ER blocking by fulvestrant was determined by stimulation with 10 nM E2 (Sigma-Aldrich) for 24 h in the presence or absence of 1 mM fulvestrant.
For IFN-b treatment, 5 Â 10 5 LNCaP cells were plated in 25 cm 2 flasks in a medium containing 10% FBS. After 24 h, 500 U/ml IFN-b1a (Pan Biotech, Aidenbach, Germany) was added to the cultures and the cells were incubated for an additional 24 h.
Tissue samples
The primary tumor samples and corresponding non-malignant prostate specimens were obtained from prostectomized PCa patients without hormonal pretreatment and from additional patients who received androgen ablation before surgery. From all patients, informed consent and histopathological classification data (UICC classification system from 2001) were obtained. The percentage of tumor cells was 60-100% in the tumor lesions and 0% in the normal prostate samples.
RNA preparation and cDNA synthesis Total RNA was isolated using the Total RNA Isolation NucleoSpin RNAII Kit (Marchery-Nagel, Du¨ren, Germany) according to the provider's instructions. After elution, 40 ml of total RNA was treated with 2 U of DNaseI in 1 Â DNase reaction buffer (Invitrogen) at 37 1C for 15 min, followed by inactivation of the enzyme at 70 1C. For cDNA synthesis with the RevertAid H Minus First Strand cDNA synthesis Kit (Fermentas, Burlington, Canada), 500 ng of RNA was reversely transcribed according to the provider's instructions using oligo(dT) 18 priming.
Quantitative PCR
The transcript levels were determined with a SYBR Green Ibased detection protocol using 12.5 ml of 2 Â Platinum SYBR Green qPCR Supermix (Invitrogen), 2 ml of 1:10 diluted cDNA, 0.5 mM of each exon-spanning primer (Supplementary information 11) and 10 nM fluorescein (Invitrogen), in a 25 ml PCR. The amplifications were carried out with a PCR protocol consisting of a pre-denaturation step (1 min at 95 1C) and 40 amplification cycles (30 s at 95 1C, 15 s at variable annealing temperatures, 15 s at 72 1C). The annealing temperatures were 63 1C each for ISG15, Ube1L, UbcH8, PSA, AR and hypoxanthine guanine phoshoribosyltransferase (HPRT) amplifications, 55 1C for EFP PCR, 60 1C for Herc5 amplification and 58 1C for b-actin PCR. To generate standards for the determination of copy numbers, all PCR fragments were cloned into the pCR2.1-TOPO cloning vector (Invitrogen). Serial dilutions of these plasmids (10-10 7 copies/tube) were included in each PCR run. All amplifications were carried out twice. The mRNA copy numbers were adjusted to the transcript copies of b-actin or HPRT.
Plasmid construction and overexpression of ISG15, Ube1L and UbcH8
For the recombinant overexpression of 6xHis-tagged ISG15, the N-terminal His-tag, including the Kozak sequence and overhangs for cloning, was obtained by hybridization of the oligonucleotide pair, His_for (5 0 -gatccgccaccatggggggttctcatca tcatcatcatcatggtgctagcc-3 0 ) and His_rev (5 0 -tcgaggctagcaccatg atgatgatgatgatgagaaccccccatggtggcg-3 0 ), and inserted into the BamHI and XhoI sites of the vector, pCMV-IRES-Neo (Jung et al., 1999) . The open reading frame of ISG15, excluding the start codon, was amplified inserting the flanking restriction sites for cloning into the XhoI and XbaI sites by the primer pair, ISG15P_for (5 0 -ctcgagggctgggacctgacggtga-3 0 ) and ISG15P_rev (5 0 -tctagattagcctccccgcaggcgca-3 0 ). The N-terminal myc-tag was generated by hybridization of the oligonucleotides, myc_for (5 0 -aattcgccaccatggaacaaaaactcatctcagaagaggatctgggaagcttggat-3 0 ) and myc_rev (5 0 -atccaagcttcccagatcctc ttctgagatgagtttttgttccatggtggcg-3 0 ), and inserted into the EcoRI and EcoRV sites of pCMV-IRES-Neo. The Ube1L and UbcH8 open reading frames were amplified excluding the start codons by the primer pairs, Ube1LP_for (5 0 -gatatcgat gccctggacgcttcg-3 0 )/Ube1LP_rev (5 0 -gcggccgctcacagctcatagtgc agag-3 0 ) and UbcH8P_for (5 0 -gatatcatggcgagcatgcgagtggtg-3 0 )/UbcH8P_rev (5 0 -gcggccgcttaggagggccggtccact-3 0 ), respectively, to allow cloning into the EcoRV and NotI sites of the vector.
LNCaP and PC-3 cells were transfected with Lipofectamine 2000 (Invitrogen) according to the provider's instructions. For transient overexpression, the cells were harvested 48 h after transfection. Bulk cultures stably overexpressing His-ISG15 or myc-Ube1L were maintained in the presence of 500 mg/ml G418 (PAA Laboratories). VCaP cells were plated in 25 cm 2 culture flasks and transfected 24 h later with 250 pmol of the respective siRNA or a control RNA with a similar GC content (medGC or low GC, respectively; Invitrogen) using Lipofectamine 2000. The cells were harvested at the indicated time points. When AR and p53 knockdowns were combined with androgen stimulation, starving was started 24 and 48 h after AR siRNA and p53 siRNA transfection, respectively, in a medium without FBS for another 24 h, and a subsequent stimulation with androgens for 24 h.
Western blot analysis
A total of 50 mg total protein was separated by SDSpolyacrylamide gel electrophoresis in 10% gels (for mycUbe1L, AR and p53) or 16% gels (for His-ISG15) and transferred to nitrocellulose membranes by semi-dry blotting for 90 min (10% gels) or 60 min (16% gels). For analysis of myc-Ube1L, AR and p53, the membranes were blocked in 1% of bovine serum albumin for 2 h at room temperature (RT), followed by staining for 2 h at RT with a mouse anti-myc antibody (1:2500; Invitrogen) or a mouse anti-AR antibody (1:250; BD Pharmingen, Heidelberg, Germany) and overnight at 4 1C with a mouse anti-p53 antibody (1:500, Glostrup, Denmark) as primary antibodies, and peroxidase-conjugated polyclonal goat or rabbit anti-mouse immunoglobulins (1:1000; Dako, Glostrup, Denmark) as secondary antibodies for 1 h at RT. For His-ISG15 detection, the membranes were blocked in 10% horse serum and 5% non-fat dry milk for 2 h at RT. The blots were then incubated with a rabbit anti-ISG15 antibody (1:250; Rockland Immunochemicals, Gilbertsville, PA, USA) for 3 h at RT and with goat anti-rabbit immunoglobulins (DAKO) for 1 h. The detection of b-actin (mouse anti-human b-actin; Abcam, Cambridge, UK) served as loading control. The immune complexes were detected by Lumi Light Western Blotting Substrate (Roche, Basel, Switzerland).
Cell proliferation assays
Cell proliferation was determined by XTT assays (Cell proliferation Kit II; Roche). The doubling time was determined by plating 1 Â 10 3 LNCaP cells or 5 Â 10 2 PC-3 cells in Corning CellBIND 96-well clear flat bottom polystyrene microplates (Corning Incorporated, Corning, NY, USA) in 200 ml of medium, with 10% FBS per well as hexaplicates, and cultivated for the indicated time periods. For the determination of androgen-induced proliferation, the cells were starved in FBSfree medium for 24 h and then plated in 100 ml of medium, with 10% CTF at 8 Â 10 3 LNCaP cells or 5 Â 10 2 PC-3 cells per well as hexaplicates. After 24 h, 100 ml medium with 10% CTF containing different concentrations of R1881 or DHT, or 100 ml medium with or without dimethyl sulfoxide as controls, was added. The proliferation was determined 4 days later by XTT assays according to the manufacturer's instructions.
In additional cell counting experiments, 1 Â 10 5 LNCaP cells or 5 Â 10 4 PC-3 cells were seeded in 25 cm 2 flasks in medium containing 10% FBS. After 24 h, the cells were starved for an additional 48 h, then stimulated with androgens in a medium with 10% CTF and counted after 4 days.
Statistics
In areas not indicated, the unpaired Student's t-test was used to evaluate statistically significant (Po0.05) and highly significant (Po0.01) differences.
